Does the media prefer DNTH or XERS?

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Dianthus Therapeutics' score of 0.47 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to XERS or TNGX?

In the previous week, Xeris Biopharma and Xeris Biopharma both had 2 articles in the media. Xeris Biopharma's average media sentiment score of 1.53 beat Tango Therapeutics' score of 0.34 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ERAS or XERS?

Xeris Biopharma has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Xeris Biopharma $291.85M 4.26 $550K $0.06 120.00

Is ERAS or XERS more profitable?

Xeris Biopharma has a net margin of 3.81% compared to Erasca's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Xeris Biopharma 3.81% 735.00% 3.24%

Does the media prefer ERAS or XERS?

In the previous week, Erasca had 28 more articles in the media than Xeris Biopharma. MarketBeat recorded 30 mentions for Erasca and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Erasca's score of 0.01 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 2 Positive mention(s) 23 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor XERS or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Oruka Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Oruka Therapeutics' score of 0.57 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Oruka Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, MANE or XERS?

Xeris Biopharma has higher revenue and earnings than Veradermics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A Xeris Biopharma $291.85M 4.26 $550K $0.06 120.00

Does the media refer more to MANE or XERS?

In the previous week, Veradermics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 3 mentions for Veradermics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Veradermics' score of 0.94 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Xeris Biopharma (XERS) Competitors

$7.20 +0.30 (+4.35%)

Closing price 04:00 PM Eastern

Extended Trading

$7.24 +0.04 (+0.56%)

As of 07:19 PM Eastern

Compare

XERS vs. DNTH, TNGX, ERAS, ORKA, and MANE

Should you buy Xeris Biopharma stock or one of its competitors? MarketBeat compares Xeris Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xeris Biopharma include Dianthus Therapeutics (DNTH), Tango Therapeutics (TNGX), Erasca (ERAS), Oruka Therapeutics (ORKA), and Veradermics (MANE). These companies are all part of the "pharmaceutical products" industry.

How does Xeris Biopharma compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Dianthus Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Dianthus Therapeutics' score of 0.47 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Dianthus Therapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Dianthus Therapeutics presently has a consensus price target of $117.82, suggesting a potential upside of 34.60%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 50.00%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 4.4% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Xeris Biopharma has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,345.72	-$162.34M	-$4.13	N/A
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00

Xeris Biopharma has a net margin of 3.81% compared to Dianthus Therapeutics' net margin of -12,998.50%. Xeris Biopharma's return on equity of 735.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%
Xeris Biopharma	3.81%	735.00%	3.24%

Summary

Xeris Biopharma beats Dianthus Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Tango Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 50.00%. Tango Therapeutics has a consensus target price of $38.42, indicating a potential upside of 35.32%. Given Xeris Biopharma's higher probable upside, equities analysts plainly believe Xeris Biopharma is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Xeris Biopharma and Xeris Biopharma both had 2 articles in the media. Xeris Biopharma's average media sentiment score of 1.53 beat Tango Therapeutics' score of 0.34 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma has a net margin of 3.81% compared to Tango Therapeutics' net margin of -151.15%. Xeris Biopharma's return on equity of 735.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Xeris Biopharma has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00
Tango Therapeutics	$62.38M	65.83	-$101.59M	-$0.83	N/A

Summary

Xeris Biopharma beats Tango Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Erasca?

Erasca (NASDAQ:ERAS) and Xeris Biopharma (NASDAQ:XERS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Erasca had 28 more articles in the media than Xeris Biopharma. MarketBeat recorded 30 mentions for Erasca and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Erasca's score of 0.01 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	2 Positive mention(s)	23 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Erasca presently has a consensus target price of $20.11, indicating a potential upside of 33.45%. Xeris Biopharma has a consensus target price of $10.80, indicating a potential upside of 50.00%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Xeris Biopharma has a net margin of 3.81% compared to Erasca's net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Xeris Biopharma	3.81%	735.00%	3.24%

67.8% of Erasca shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Erasca has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Xeris Biopharma has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00

Summary

Xeris Biopharma beats Erasca on 10 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Oruka Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Xeris Biopharma presently has a consensus price target of $10.80, indicating a potential upside of 50.00%. Oruka Therapeutics has a consensus price target of $131.30, indicating a potential upside of 57.43%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Xeris Biopharma has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for Oruka Therapeutics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Oruka Therapeutics' score of 0.57 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Oruka Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of 3.81% compared to Oruka Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Xeris Biopharma has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Summary

Xeris Biopharma beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Xeris Biopharma compare to Veradermics?

Veradermics (NYSE:MANE) and Xeris Biopharma (NASDAQ:XERS) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

In the previous week, Veradermics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 3 mentions for Veradermics and 2 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 1.53 beat Veradermics' score of 0.94 indicating that Xeris Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Xeris Biopharma has higher revenue and earnings than Veradermics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00

42.8% of Xeris Biopharma shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Xeris Biopharma has a net margin of 3.81% compared to Veradermics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Xeris Biopharma	3.81%	735.00%	3.24%

Veradermics currently has a consensus price target of $114.20, suggesting a potential upside of 9.93%. Xeris Biopharma has a consensus price target of $10.80, suggesting a potential upside of 50.00%. Given Xeris Biopharma's higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Xeris Biopharma beats Veradermics on 8 of the 11 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.19B	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	120.00	18.43	24.92	23.98
Price / Sales	4.26	327.41	528.51	109.04
Price / Cash	68.89	56.31	44.82	54.51
Price / Book	90.00	4.11	10.79	6.50
Net Income	$550K	$64.45M	$3.56B	$336.88M
7 Day Performance	4.35%	2.24%	1.67%	-0.22%
1 Month Performance	16.32%	1.04%	0.43%	0.77%
1 Year Performance	55.17%	30.05%	32.84%	31.57%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.3159 of 5 stars	$7.20 +4.3%	$10.80 +50.0%	+53.0%	$1.19B	$291.85M	120.00	290	Positive News
DNTH Dianthus Therapeutics	2.4154 of 5 stars	$82.51 +0.5%	$117.82 +42.8%	+418.5%	$4.49B	$2.04M	N/A	80
TNGX Tango Therapeutics	2.3803 of 5 stars	$32.90 +6.3%	$38.42 +16.8%	+452.3%	$4.48B	$62.38M	N/A	90
ERAS Erasca	2.4812 of 5 stars	$14.43 +2.7%	$20.11 +39.4%	+1,000.7%	$4.37B	N/A	N/A	120	Trending News Options Volume
ORKA Oruka Therapeutics	3.1069 of 5 stars	$68.86 -1.5%	$131.30 +90.7%	+631.0%	$4.22B	N/A	N/A	N/A	News Coverage Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. DNTH, TNGX, ERAS, ORKA, and MANE

How does Xeris Biopharma compare to Dianthus Therapeutics?

Summary

How does Xeris Biopharma compare to Tango Therapeutics?

Summary

How does Xeris Biopharma compare to Erasca?

Summary

How does Xeris Biopharma compare to Oruka Therapeutics?

Summary

How does Xeris Biopharma compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. DNTH, TNGX, ERAS, ORKA, and MANE

How does Xeris Biopharma compare to Dianthus Therapeutics?

Does the media prefer DNTH or XERS?

Which has more volatility and risk, DNTH or XERS?

Do analysts rate DNTH or XERS?

Do insiders and institutionals have more ownership in DNTH or XERS?

Which has higher earnings & valuation, DNTH or XERS?

Is DNTH or XERS more profitable?

Summary

How does Xeris Biopharma compare to Tango Therapeutics?

Do institutionals & insiders believe in XERS or TNGX?

Do analysts prefer XERS or TNGX?

Does the media refer more to XERS or TNGX?

Is XERS or TNGX more profitable?

Which has more risk and volatility, XERS or TNGX?

Which has higher valuation and earnings, XERS or TNGX?

Summary

How does Xeris Biopharma compare to Erasca?

Does the media prefer ERAS or XERS?

Do analysts rate ERAS or XERS?

Is ERAS or XERS more profitable?

Do insiders and institutionals believe in ERAS or XERS?

Which has more volatility and risk, ERAS or XERS?

Which has preferable earnings & valuation, ERAS or XERS?

Summary

How does Xeris Biopharma compare to Oruka Therapeutics?

Do analysts prefer XERS or ORKA?

Do institutionals & insiders believe in XERS or ORKA?

Which has more volatility & risk, XERS or ORKA?

Does the media favor XERS or ORKA?

Is XERS or ORKA more profitable?

Which has stronger earnings & valuation, XERS or ORKA?

Summary

How does Xeris Biopharma compare to Veradermics?

Does the media refer more to MANE or XERS?

Which has better valuation and earnings, MANE or XERS?

Do institutionals & insiders hold more shares of MANE or XERS?

Is MANE or XERS more profitable?

Do analysts recommend MANE or XERS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools